H.R. 5160 · 119th Congress · Health
Stem Cell Therapeutic and Research Reauthorization Act of 2025
How the House voted
Yea from the left, nay from the right, each side by party
House · Jul 20, 2026
Passed by voice vote.
Passed the House on July 20, 2026.
Latest action: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464
- IntroducedSep 4, 2025
- CommitteeJul 2, 2026
- Passed HouseJul 20, 2026
- Passed Senate
- Became law
On the record
- Cosponsors
- 21
- 11 Democrats, 10 Republicans
- House committee
- Energy and Commerce
- Lobbying
- At least 8
- organizations named it2025 Q3 to 2026 Q3
What it does
The bill reauthorizes the Stem Cell Therapeutic and Research Act of 2005, extending the federal stem cell and cord blood transplantation programs through fiscal year 2031.
The bill reauthorizes the Stem Cell Therapeutic and Research Act of 2005, extending the federal stem cell and cord blood transplantation programs through fiscal year 2031. It authorizes $33,009,000 for each of fiscal years 2027 through 2031 for the C.W. Bill Young Cell Transplantation Program, the national bone marrow and cord blood matching program. It replaces the National Cord Blood Inventory's fixed target of at least 150,000 new units with "a sufficient supply, as determined by the Secretary," of high-quality cord blood units. It directs the Secretary to manage the inventory's size and composition to maximize clinical utility and genetic diversity, and it lets the Secretary transfer units from a cord blood bank that is no longer operational to another qualified bank.
Each stop is a step the bill’s own record states, with the date it happened. A ring is a step not yet taken. A bill becomes law when the President signs it or Congress overrides a veto.
At least 8 organizations named this measure in a lobbying filing. A floor, not a total: they were counted by the client name on 23 quarterly reports filed by 4 lobbying firms and by 4 organizations lobbying for themselves in 2025 Q3, 2025 Q4, 2026 Q1, 2026 Q2 and 2026 Q3. An organization that lobbied this measure without naming it is not counted here.
The filings record that lobbying was reported on the measure. The form has no per-bill dollar figure and no field for a position, so nothing here says how much was spent or which side an organization took.
5 of them, in no ranking: Nmdp; Astct; National Marrow Donor Program; American Association of Blood Banks, dba Association for the Advancement of Bloo; American Benefits Council. Listed as filed, in the order the filings were read, and 3 others are not shown. These are not the largest, the earliest or the most active: we keep five names per measure, and the filings give no ranking.
From the LD-2 quarterly lobbying filings published at lda.gov by the Senate Office of Public Records. Read for 2025 Q1, 2025 Q2, 2025 Q3, 2025 Q4, 2026 Q1, 2026 Q2 and 2026 Q3. Our copy holds 24 fewer filings for 2025 Q1, 39 fewer filings for 2025 Q2, 42 fewer filings for 2025 Q3, 33 fewer filings for 2025 Q4, 28 fewer filings for 2026 Q1, 48 fewer filings for 2026 Q2 and 218 fewer filings for 2026 Q3 than the Senate's register counts, so those quarters are the filings we could read rather than every one filed. 2026 Q4 is still inside its filing window, so that quarter is only the filings posted so far.
Congress.gov bill status and cosponsor records; the House Clerk and Senate roll calls; lobbying reports filed under the Lobbying Disclosure Act (lda.gov); the plain summary and provisions are read from the bill text, each with its section.